Vimarsana
Biggest News Aggregation in the World

Elevai Labs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Elevai Labs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Elevai Labs Today - Breaking & Trending Today

Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference - Vimarsana News

Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference

NEWPORT BEACH, Calif., May 22, 2024 -- Elevai Labs Inc. , a pioneering force in medical aesthetics, announced that Chief Executive Officer Dr. Jordan R. Plews, PhD will be presenting at the Los...

Certain Common Stock of Elevai Labs, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. - Vimarsana News

Certain Common Stock of Elevai Labs, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024.

Certain Common Stock of Elevai Labs, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2024. These Common Stock will be under lockup for 181 days starting from 20-NOV-2023 to...

Wall Street Breakfast: The Week Ahead - Vimarsana News

Wall Street Breakfast: The Week Ahead

This article highlights upcoming events in the financial world, including quarterly earnings reports, IPOs, investor events, and market volatility updates.

Elevai Labs, Inc. (NASDAQ:ELAB) Short Interest Up 52.9% in April - Vimarsana News

Elevai Labs, Inc. (NASDAQ:ELAB) Short Interest Up 52.9% in April

Elevai Labs, Inc. (NASDAQ:ELAB – Get Free Report) saw a significant growth in short interest in the month of April. As of April 30th, there was short interest totalling 83,800 shares, a growth of 52.9% from the April 15th total of 54,800 shares. Based on an average daily volume of 370,600 shares, the short-interest ratio […]

Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset "EL-22" for The Treatment of Obesity - Vimarsana News

Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset "EL-22" for The Treatment of Obesity

Preclinical results of EL-22 from a 2022 study demonstrated physiological , physical , and functional improvements in the dystrophic features of mdx mice, a mouse model of Duchenne muscular dystrophy...